Category Archives: Generics / ANDA

Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc.

Docket No. 2016-1731 NEWMAN, MOORE, WALLACH May 5, 2017 Non-precedential Brief Summary: DC claim construction (e.g., previous Novel decision “foreclosed the [DC’s] construction of ‘from about 100 ml to about 500 ml’”) and infringement decisions reversed (e.g., claimed effects of … Continue reading

Posted in Claim Construction, Generics / ANDA, Inducement to Infringe, Infringement | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: FC panel reversed DC and found the asserted claims invalid under the § 102(b) on-sale bar. The FC panel concluded that the AIA did not change the meaning … Continue reading

Posted in America Invents Act, Anticipation (35 USC 102), Generics / ANDA, On-Sale Bar | Leave a comment

The Medicines Company v. Mylan, Inc. et al.

Docket No. 2015-1113, -1151, -1181 DYK, WALLACH, HUGHES April 6, 2017 Brief Summary: DC’s finding of infringement of the ‘727 patent reversed based on FC’s reading its construction of “efficient mixing” into the claims, thereby requiring infringing batches to “be … Continue reading

Posted in Claim Construction, Generics / ANDA | Leave a comment

Shire Development, LLC et al. v. Watson Pharmaceuticals, Inc. et al.

Docket No. 2016-1785 PROST, TARANTO, HUGHES February 10, 2017 Brief Summary: DC decision that Watson’s ANDA Product to Shire’s Lialda® reversed for not meeting the Markush requirements of the claims. Summary: Shire sued Watson for infringement of US 6,773,720 directed … Continue reading

Posted in Claim Construction, Generics / ANDA, Infringement | 2 Comments

Mylan Laboratories Ltd. v. Aventis Pharma S.A.

IPR2016-00627 August 23, 2016 Brief Summary: Mylan’s Petition requesting IPR regarding claims 1 and 2 of Aventis’ US 5,847,170 encompassing the taxoid cabazitaxel (Jevtana®) denied. Summary: Mylan filed a Petition requesting IPR of claims 1 and 2 of Aventis’ US … Continue reading

Posted in Generics / ANDA, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Apotex Inv. V. Wyeth LLC

Docket No. 2015-1871 (IPR2014-00115) LOURIE, WALLACH, HUGHES August 16, 2016 Non-precedential Brief Summary: PTAB final written decision of nonobviousness affirmed because “Apotex failed to explain why a skilled artisan ‘would have substituted tigecycline for minocycline’”. Summary: Apotex appealed PTAB final … Continue reading

Posted in Claim Construction, Generics / ANDA, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Amgen Inc. et al. v. Apotex Inc. et al.

Docket No. 2016-1308 WALLACH, BRYSON, TARANTO July 5, 2016 Update: Petition for a writ of certiorari denied (12/12/16) Brief Summary: DC grant of preliminary injunction against Apotex regarding a biosimilar Neulasta® affirmed (“an applicant must provide a reference product sponsor … Continue reading

Posted in Biosimilars, Generics / ANDA | Leave a comment